Business Description
ProQR Therapeutics NV
NAICS : 541714
SIC : 2836
ISIN : NL0010872495
Total Employee Number:
187Description
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.15 | |||||
Equity-to-Asset | 0.38 | |||||
Debt-to-Equity | 0.42 | |||||
Debt-to-EBITDA | -0.38 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -5.91 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 49.5 | |||||
3-Year EBITDA Growth Rate | 20 | |||||
3-Year EPS without NRI Growth Rate | 22.3 | |||||
3-Year FCF Growth Rate | 16.4 | |||||
3-Year Book Growth Rate | -14.5 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 59.27 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.48 | |||||
Quick Ratio | 2.48 | |||||
Cash Ratio | 2.31 | |||||
Days Sales Outstanding | 105.39 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -9.2 | |||||
Shareholder Yield % | 0.07 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -344.34 | |||||
Net Margin % | -338.45 | |||||
EBITDA Margin % | -307.53 | |||||
FCF Margin % | -364.7 | |||||
OCF Margin % | -357.6 | |||||
ROE % | -79.92 | |||||
ROA % | -36.98 | |||||
ROIC % | -102.6 | |||||
3-Year ROIIC % | -67.07 | |||||
ROC (Joel Greenblatt) % | -346.03 | |||||
ROCE % | -48.96 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 12.26 | |||||
PB Ratio | 4.39 | |||||
Price-to-Tangible-Book | 4.43 | |||||
EV-to-EBIT | -2.28 | |||||
EV-to-EBITDA | -2.43 | |||||
EV-to-Revenue | 7.48 | |||||
EV-to-Forward-Revenue | 17.1 | |||||
EV-to-FCF | -2.04 | |||||
Price-to-GF-Value | 0.9 | |||||
| Price-to-Net-Current-Asset-Value | 6.49 | |||||
| Price-to-Net-Cash | 8.26 | |||||
Earnings Yield (Greenblatt) % | -43.86 | |||||
FCF Yield % | -29.89 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ProQR Therapeutics NV Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 287.209 | ||
| EPS (TTM) (MXN) | -9.166 | ||
| Beta | -0.0232 | ||
| 3-Year Sharpe Ratio | 0.09 | ||
| 3-Year Sortino Ratio | 0.63 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (MXN) | - | ||
| 20-Day SMA (MXN) | 36 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (MXN) | 36 - 36 | ||
| Shares Outstanding (Mil) | 105.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ProQR Therapeutics NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ProQR Therapeutics NV Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 134 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 43 days | ||
| General meeting for 2026 | 2026-06-02 15:00 | 36.00 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 36.00 (+0.00%) | ||
| Virtual Investor and Analyst Event | 2026-04-08 10:00 | 36.00 (+0.00%) | ||
| Annual report for 2025 | 2026-03-12 | 36.00 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-12 | 36.00 (+0.00%) | ||
| Citizens Life Sciences Conference | 2026-03-11 15:25 | 36.00 (+0.00%) | ||
| 8th Annual Evercore Healthcare Conference | 2025-12-04 08:20 | 36.00 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-06 | 36.00 (+0.00%) |
Show
Entries
ProQR Therapeutics NV Frequently Asked Questions
What is ProQR Therapeutics NV(MEX:PRQRN)'s stock price today?
The current price of MEX:PRQRN is MXN36.00. The 52 week high of MEX:PRQRN is MXN36.00 and 52 week low is MXN36.00.
When is next earnings date of ProQR Therapeutics NV(MEX:PRQRN)?
The next earnings date of ProQR Therapeutics NV(MEX:PRQRN) is 2026-08-07 Est..
Does ProQR Therapeutics NV(MEX:PRQRN) pay dividends? If so, how much?
ProQR Therapeutics NV(MEX:PRQRN) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Thinking about buying stock in Plus Therapeutics, AMC Entertainment, ProQR Therapeutics, Nokia, or Diana Shipping? | 2021-05-04 |
Articles on ProQR Therapeutics NV
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers